Skip to Main Content

Correction to: New Approved Vaccines for Respiratory Syncytial Virus (RSV)

Date: 01/16/24

RSV is the leading cause of childhood respiratory illness in the United States, resulting in thousands of hospitalizations and hundreds of deaths per year.

As a trusted partner, we are committed to providing you timely information that helps promote shared decision making so Iowa Total Care members can make informed decisions on how to best protect their infant against RSV.

The following codes for RSV vaccine have been added to the fee schedules and are now effective and approved for use:

Abrysvo

  • 90678 Vaccine.
  • 90471 Vaccine administration.

Note: Abrysvo is approved for use in pregnant individuals who are between 32 – 36 weeks gestation, to offer protection to their infants. It is also approved for use in members aged 60+.

Arexvy

  • 90679 Vaccine.
  • 90471 Vaccine administration.

Note: Arexvy is approved for use in members aged 60+.

Beyfortus

  • 90380 Vaccine, 0.5 mL dose.
  • 90381 Vaccine, 1 mL dose.
  • 90471 Vaccine administration.
  • 96372 Vaccine administration, Vaccines for Children (VCF) Program.

Note: Beyfortus is approved for use in newborns and children up to 24 months old who remain at increased risk for severe RSV disease in their second RSV season.

For further information regarding codes for RSV vaccines refer to Informational Lettera 2521-MC-FFS and 2522-MC-FFS found on the Iowa Medicaid Informational Letters webpage.

For questions or concerns, contact your Provider Relations Specialist or call Provider Services at 1-833-404-1061.

Thank you for your partnership in serving Iowa Total Care members.